Medical School · Year 2 · Pharmacology · includes a quiz and discussion video

Lecture 06: Antimicrobial Pharmacology

Unit 2.12: Pharmacology

Learning Objectives

By the end of this lecture, students will be able to:

1. Describe the mechanisms and spectrum of beta-lactam antibiotics
2. Explain protein synthesis inhibitors
3. Describe fluoroquinolones and DNA synthesis inhibitors
4. Explain antifungal and antiviral agents
5. Describe antiparasitic drugs
6. Explain antimicrobial resistance and stewardship

Lecture Outline

I. Antimicrobial Principles

Antimicrobial agents represent one of the most important therapeutic classes in medicine, providing essential tools for treating infectious diseases caused by bacteria, fungi, viruses, and parasites. The fundamental principle underlying antimicrobial therapy is selective toxicity, whereby drugs exploit differences between microbial and human cellular machinery to kill or inhibit pathogens while minimizing harm to host tissues. Understanding the various mechanisms of action allows clinicians to select appropriate agents based on the suspected or confirmed pathogen and the site of infection. The development of antimicrobial agents has transformed medicine, converting previously fatal infections into manageable conditions, though the emergence of resistance threatens these gains.

Antimicrobial mechanisms of action can be categorized by their cellular targets, with each target representing a vital pathway or structure in the microorganism. Cell wall synthesis inhibitors, including beta-lactams and glycopeptides, target the peptidoglycan layer unique to bacterial cells, causing osmotic lysis and cell death. Protein synthesis inhibitors bind to bacterial ribosomes, which differ structurally from human ribosomes, blocking translation at either the 30S or 50S subunit. DNA and RNA synthesis inhibitors target enzymes essential for nucleic acid replication, including DNA gyrase, topoisomerase IV, and RNA polymerase, while folate synthesis inhibitors exploit the bacterial requirement to synthesize folate de novo, a pathway absent in humans who obtain folate from diet.

The classification of antimicrobials as bactericidal or bacteriostatic has important clinical implications, particularly in immunocompromised patients and severe infections. Bactericidal agents, including beta-lactams, aminoglycosides, and fluoroquinolones, actively kill bacteria by disrupting essential cellular processes, achieving a 99.9% reduction in bacterial count. Bacteriostatic agents, such as macrolides and tetracyclines, inhibit bacterial growth without directly killing organisms, relying on host immune defenses to clear the infection. Some agents exhibit context-dependent activity, behaving as bactericidal under certain conditions and bacteriostatic under others, depending on the organism, drug concentration, and site of infection.

Pharmacokinetic and pharmacodynamic properties determine optimal dosing strategies for antimicrobial agents, with different drug classes requiring different approaches to maximize efficacy. Time-dependent antibiotics, exemplified by beta-lactams, exhibit optimal killing when drug concentrations remain above the minimum inhibitory concentration for extended periods, favoring frequent dosing or continuous infusions. Concentration-dependent antibiotics, including aminoglycosides and fluoroquinolones, achieve maximal bactericidal activity at high peak concentrations relative to the MIC, supporting once-daily dosing regimens. AUC-dependent antibiotics, such as vancomycin, require optimization of the total drug exposure over 24 hours relative to the MIC, necessitating careful monitoring and dose adjustment based on therapeutic drug monitoring.

<image>Panel A: Detailed bacterial cell with labeled targets for different antibiotic classes showing cell wall targeted by beta-lactams and glycopeptides, ribosomes targeted by aminoglycosides, macrolides, and tetracyclines, DNA gyrase targeted by fluoroquinolones, RNA polymerase targeted by rifampin, and folate pathway targeted by sulfonamides and trimethoprim. Panel B: Comparison chart of bactericidal versus bacteriostatic activity with time-kill curves showing logarithmic bacterial counts over time and the 99.9% kill threshold for bactericidal agents. Panel C: Pharmacokinetic/pharmacodynamic parameter graphs showing time-dependent killing with time above MIC, concentration-dependent killing with Cmax/MIC ratio, and AUC-dependent killing with AUC/MIC ratio. Panel D: Spectrum diagram with concentric circles representing gram-positive, gram-negative, atypical, and anaerobic bacteria with shaded regions indicating antibiotic class coverage patterns.</image>

II. Beta-Lactam Antibiotics

Beta-lactam antibiotics constitute the most widely prescribed class of antimicrobials, sharing a common four-membered beta-lactam ring essential for their bactericidal activity. The mechanism of action involves binding to penicillin-binding proteins, which are transpeptidase enzymes responsible for cross-linking peptidoglycan chains during bacterial cell wall synthesis. By inhibiting these enzymes, beta-lactams prevent proper cell wall formation, leading to osmotic instability and bacterial lysis during growth and division. The bactericidal activity of beta-lactams is time-dependent, meaning clinical efficacy depends on maintaining drug concentrations above the MIC for 40-70% of the dosing interval.

Penicillins represent the original beta-lactam antibiotics, with several subclasses developed to expand spectrum and overcome resistance. Natural penicillins, including penicillin G for intravenous use and penicillin V for oral administration, retain excellent activity against streptococci and susceptible staphylococci, remaining first-line agents for streptococcal pharyngitis and syphilis. Antistaphylococcal penicillins, such as nafcillin and oxacillin, resist staphylococcal penicillinase through bulky side chains that prevent enzyme access to the beta-lactam ring, making them drugs of choice for methicillin-susceptible Staphylococcus aureus infections. Aminopenicillins, including ampicillin and amoxicillin, extend coverage to some gram-negative organisms like Haemophilus influenzae and Escherichia coli, while antipseudomonal penicillins such as piperacillin provide activity against Pseudomonas aeruginosa when combined with beta-lactamase inhibitors.

Cephalosporins are organized into generations based on their spectrum of activity, with each successive generation generally providing expanded gram-negative coverage at the expense of gram-positive activity. First-generation cephalosporins, such as cefazolin and cephalexin, offer excellent gram-positive coverage and are commonly used for surgical prophylaxis and skin and soft tissue infections. Second-generation agents like cefuroxime add coverage for respiratory pathogens and some gram-negative organisms, while cefoxitin provides anaerobic activity useful for intra-abdominal infections. Third-generation cephalosporins, including ceftriaxone and ceftazidime, achieve excellent gram-negative coverage with central nervous system penetration, serving as first-line agents for community-acquired pneumonia and meningitis. Fourth-generation cefepime combines broad gram-negative coverage including Pseudomonas with retained gram-positive activity, while fifth-generation ceftaroline uniquely provides activity against MRSA.

Carbapenems represent the broadest-spectrum beta-lactams, reserved for serious infections and resistant organisms due to their extensive activity and importance as last-resort agents. Imipenem is administered with cilastatin, which inhibits renal dehydropeptidase that would otherwise inactivate the drug, but carries a risk of seizures limiting its use in central nervous system infections. Meropenem provides similar broad coverage with improved CNS penetration and reduced seizure potential, making it preferred for meningitis and critically ill patients. Ertapenem offers convenient once-daily dosing but lacks Pseudomonas and Acinetobacter coverage, useful for community-acquired intra-abdominal and complicated urinary tract infections. Aztreonam, a monobactam, uniquely targets gram-negative organisms only with a chemical structure distinct enough to allow safe use in patients with severe penicillin allergy, as cross-reactivity is minimal.

<image>Panel A: Mechanism of action showing bacterial cell wall with penicillin-binding proteins (transpeptidases), peptidoglycan cross-links, and beta-lactam molecule binding to and inhibiting PBP enzyme with the four-membered beta-lactam ring structure. Panel B: Hierarchical diagram of cephalosporin generations with representative drugs for each generation from 1st through 5th, showing increasing gram-negative coverage and decreasing gram-positive coverage across generations. Panel C: Spectrum coverage chart with bacterial organisms and penicillin classes including natural, antistaphylococcal, aminopenicillins, and antipseudomonal with color-coded activity indicators. Panel D: Carbapenem and monobactam structures showing imipenem with cilastatin, meropenem, ertapenem, and aztreonam with distinguishing structural features and clinical properties.</image>

III. Other Cell Wall Inhibitors

Vancomycin remains a cornerstone of therapy for serious gram-positive infections, particularly those caused by methicillin-resistant Staphylococcus aureus and other resistant organisms. The mechanism involves binding to the D-alanine-D-alanine terminal of peptidoglycan precursors, preventing the transglycosylation step that normally polymerizes these building blocks into mature cell wall. This mechanism is distinct from beta-lactams, allowing vancomycin to retain activity against organisms that have modified their penicillin-binding proteins. Vancomycin dosing has evolved from traditional trough-based monitoring to AUC-guided dosing, targeting an AUC/MIC ratio of 400-600 to optimize efficacy while minimizing nephrotoxicity.

Vancomycin carries important toxicities that clinicians must monitor and manage throughout therapy. Nephrotoxicity occurs through uncertain mechanisms, with risk increased by concurrent nephrotoxic agents, prolonged therapy, and higher trough concentrations. Red man syndrome, a histamine-mediated infusion reaction characterized by flushing, pruritus, and hypotension, can be prevented by slowing the infusion rate and premedicating with antihistamines. Vancomycin-resistant Enterococcus has emerged as a significant clinical challenge, with resistance mediated by the vanA gene that alters the peptidoglycan precursor terminus from D-Ala-D-Ala to D-Ala-D-Lac, preventing vancomycin binding.

Daptomycin represents a novel lipopeptide antibiotic with a unique mechanism of membrane depolarization, providing bactericidal activity against gram-positive organisms including MRSA and VRE. The drug inserts into bacterial cell membranes in a calcium-dependent manner, forming channels that cause rapid depolarization, ion efflux, and cell death without cell lysis. A critical limitation is inactivation by pulmonary surfactant, rendering daptomycin ineffective for pneumonia despite excellent in vitro activity against respiratory pathogens. Monitoring creatine phosphokinase is essential during therapy due to the risk of myopathy, with drug discontinuation required if CK rises significantly or symptoms of muscle pain and weakness develop.

Beta-lactamase inhibitors have dramatically expanded the utility of existing beta-lactam antibiotics by protecting them from enzymatic degradation. Clavulanate, combined with amoxicillin, provides activity against beta-lactamase-producing organisms while adding some intrinsic activity against anaerobes. Sulbactam combined with ampicillin and tazobactam combined with piperacillin create broad-spectrum combinations effective against mixed aerobic-anaerobic infections. Newer inhibitors including avibactam and vaborbactam extend protection to organisms producing extended-spectrum beta-lactamases and even some carbapenemases, creating options for treating highly resistant gram-negative infections. These combinations, such as ceftazidime-avibactam and meropenem-vaborbactam, represent critical tools against carbapenem-resistant Enterobacteriaceae.

<image>Panel A: Vancomycin mechanism showing drug binding to D-Ala-D-Ala termini of peptidoglycan precursors and blocking transglycosylation, with comparison of how VRE alters the target to D-Ala-D-Lac preventing vancomycin binding. Panel B: Daptomycin mechanism showing the lipopeptide inserting into bacterial membrane phospholipid bilayer, forming calcium-dependent channels that cause ion efflux and membrane depolarization, with note about surfactant inactivation. Panel C: AUC-guided vancomycin dosing graph showing serum concentration over time with shaded AUC region, MIC threshold line, and target AUC/MIC ratio of 400-600. Panel D: Comparison chart of beta-lactamase inhibitors including clavulanate, sulbactam, tazobactam, avibactam, and vaborbactam with their partner drugs, spectrum of inhibition, and clinical uses.</image>

IV. Protein Synthesis Inhibitors - 30S Subunit

Aminoglycosides are bactericidal antibiotics that target the 30S ribosomal subunit, causing misreading of mRNA and production of aberrant proteins that disrupt bacterial cell membrane integrity. This class includes gentamicin, tobramycin, and amikacin, each with slightly different spectra and resistance profiles but similar mechanisms and toxicities. The bactericidal activity is concentration-dependent, with the ratio of peak concentration to MIC being the primary determinant of efficacy, supporting once-daily dosing strategies that achieve high peaks while allowing drug-free intervals that reduce toxicity. Aminoglycosides exhibit excellent gram-negative coverage and demonstrate synergy with cell wall-active agents against gram-positive organisms, making them valuable components of combination therapy for endocarditis and serious enterococcal infections.

Aminoglycoside dosing strategies have evolved based on pharmacodynamic principles and toxicity patterns. Traditional multiple-daily dosing has largely been replaced by extended-interval or once-daily dosing, which achieves higher peak concentrations for improved efficacy while allowing drug-free intervals that reduce accumulation in renal tubular cells and cochlear hair cells. Therapeutic drug monitoring with peak and trough levels guides dosing adjustments, with specific targets varying based on the dosing strategy employed. Synergy dosing uses lower doses to enhance killing when combined with beta-lactams for gram-positive infections, requiring different monitoring parameters than standard gram-negative treatment.

Tetracyclines bind reversibly to the 30S ribosomal subunit, blocking the attachment of aminoacyl-tRNA to the acceptor site and inhibiting protein synthesis. Doxycycline represents the most commonly used agent, providing excellent coverage of atypical pathogens, spirochetes causing Lyme disease, and various sexually transmitted infections. Minocycline exhibits enhanced lipophilicity with activity against some MRSA strains, while tigecycline, a glycylcycline derivative, provides broad coverage including many resistant organisms but carries FDA black box warnings regarding increased mortality in certain patient populations. Tetracyclines are bacteriostatic and contraindicated in pregnancy and children under eight years due to permanent dental staining and bone growth effects.

Tetracycline resistance has emerged through several mechanisms that compromise their clinical utility in many settings. Efflux pumps represent the most common resistance mechanism, actively transporting the drug out of bacterial cells before it can reach inhibitory concentrations at the ribosome. Ribosomal protection proteins alter the ribosome configuration, reducing tetracycline binding affinity while maintaining normal protein synthesis function. Enzymatic inactivation, though less common than other mechanisms, directly degrades the antibiotic before it can exert its effect. Understanding these resistance mechanisms has guided development of newer agents like tigecycline, which evade many common resistance determinants through structural modifications.

<image>Panel A: Aminoglycoside mechanism showing bacterial ribosome with 30S subunit binding site, mRNA misreading, and aberrant protein production leading to membrane damage and cell death. Panel B: Once-daily versus traditional aminoglycoside dosing with serum concentration graphs over 24 hours showing peak and trough markers, demonstrating higher peaks with drug-free intervals versus more constant levels. Panel C: Tetracycline binding at 30S ribosome A-site blocking aminoacyl-tRNA attachment and inhibiting protein synthesis, with doxycycline molecular structure. Panel D: Three mechanisms of tetracycline resistance showing efflux pumps removing drug from cell, ribosomal protection proteins altering ribosome configuration, and enzymatic inactivation degrading the drug.</image>

V. Protein Synthesis Inhibitors - 50S Subunit

Macrolides bind to the 50S ribosomal subunit, blocking the translocation step of protein synthesis where the growing peptide chain moves from the A-site to the P-site. Azithromycin has become the most prescribed macrolide due to its exceptionally long tissue half-life, allowing short-course therapy with once-daily dosing and excellent intracellular penetration for atypical pathogens. Clarithromycin serves as a key component of Helicobacter pylori eradication regimens and provides similar respiratory pathogen coverage, while erythromycin finds niche use as a prokinetic agent despite significant gastrointestinal side effects and drug interactions. Macrolides exhibit predominantly bacteriostatic activity, though they may achieve bactericidal concentrations against highly susceptible organisms.

Macrolide clinical applications span respiratory infections, sexually transmitted infections, and prophylaxis in immunocompromised patients. Community-acquired pneumonia treatment protocols incorporate azithromycin to cover atypical pathogens including Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella species, which are not targeted by beta-lactam monotherapy. A single dose of azithromycin effectively treats Chlamydia trachomatis infections and serves as an alternative for gonorrhea in combination regimens. Patients with advanced HIV infection receive azithromycin prophylaxis against Mycobacterium avium complex when CD4 counts fall below critical thresholds. QT prolongation represents a class effect requiring caution with concurrent use of other QT-prolonging agents and in patients with underlying cardiac conduction abnormalities.

Clindamycin binds to the 50S ribosomal subunit at a site overlapping with macrolides, inhibiting peptide chain elongation through a similar but distinct mechanism. The drug provides excellent activity against gram-positive organisms and most anaerobes, making it valuable for skin and soft tissue infections, including those caused by community-acquired MRSA. Clindamycin achieves excellent bone penetration, supporting its use in osteomyelitis, and suppresses toxin production in streptococcal and staphylococcal toxic shock syndromes. The most significant adverse effect is Clostridioides difficile-associated diarrhea and colitis, as clindamycin's broad anaerobic activity disrupts normal intestinal flora, allowing C. difficile overgrowth.

Linezolid, the first oxazolidinone antibiotic, blocks formation of the initiation complex by preventing 30S and 50S subunit joining, representing a truly novel mechanism without cross-resistance to other protein synthesis inhibitors. This unique mechanism provides reliable activity against virtually all gram-positive organisms, including vancomycin-resistant Enterococcus and methicillin-resistant Staphylococcus aureus, making linezolid a critical option for resistant infections. The drug achieves excellent oral bioavailability approaching 100%, allowing step-down from intravenous to oral therapy without compromising efficacy. Significant toxicities include reversible myelosuppression requiring weekly complete blood count monitoring during prolonged therapy, and serotonin syndrome risk when combined with serotonergic agents including SSRIs and MAO inhibitors, as linezolid possesses weak MAO-inhibiting activity.

<image>Panel A: Macrolide mechanism showing ribosome with 50S binding site, translocation step being blocked, and growing peptide chain unable to move from A-site to P-site, with azithromycin, clarithromycin, and erythromycin molecular structures. Panel B: Clinical applications of macrolides including community-acquired pneumonia for atypical coverage, STI treatment for chlamydia and gonorrhea, H. pylori eradication with clarithromycin, and MAC prophylaxis with azithromycin, with QT prolongation warning. Panel C: Clindamycin binding to 50S subunit with spectrum coverage of gram-positives, anaerobes, and toxin suppression, plus mechanism of C. difficile colitis through disruption of normal intestinal flora. Panel D: Linezolid mechanism preventing 30S-50S joining and initiation complex formation, with VRE and MRSA spectrum, near 100% oral bioavailability, and toxicity warnings for myelosuppression and serotonin syndrome risk.</image>

VI. DNA Synthesis Inhibitors

Fluoroquinolones inhibit bacterial DNA gyrase and topoisomerase IV, essential enzymes for DNA replication, transcription, and repair, causing DNA strand breaks and rapid bactericidal killing. Second-generation fluoroquinolones, exemplified by ciprofloxacin, provide excellent gram-negative coverage including Pseudomonas aeruginosa but limited gram-positive activity, making them ideal for urinary tract infections and certain gastrointestinal infections. Third-generation levofloxacin adds enhanced activity against respiratory pathogens including Streptococcus pneumoniae, earning designation as a respiratory fluoroquinolone suitable for community-acquired pneumonia. Fourth-generation moxifloxacin further extends the spectrum to include anaerobic coverage while maintaining respiratory pathogen activity, though lacking urinary tract infection utility due to inadequate urinary excretion.

The differential targeting of DNA gyrase versus topoisomerase IV determines species-specific activity patterns of fluoroquinolones. In gram-negative bacteria, DNA gyrase serves as the primary target, with mutations in this enzyme conferring first-step resistance and topoisomerase IV mutations adding higher-level resistance. Conversely, gram-positive organisms show primary dependence on topoisomerase IV, explaining the enhanced gram-positive activity of newer respiratory fluoroquinolones designed to better inhibit this enzyme. This dual-target mechanism means that clinical resistance typically requires sequential mutations in both enzymes, providing some barrier to resistance development compared to single-target antibiotics.

Fluoroquinolone toxicities have received increasing regulatory attention, with FDA black box warnings highlighting serious adverse effects that may limit their use. Tendon rupture, particularly of the Achilles tendon, occurs with increased frequency in patients over 60 years of age, those receiving concurrent corticosteroids, and organ transplant recipients on immunosuppression. QT prolongation can precipitate torsades de pointes, requiring caution with concurrent QT-prolonging drugs and in patients with electrolyte abnormalities. Central nervous system effects including seizures and psychosis, glucose dysregulation with both hypoglycemia and hyperglycemia, and potentially permanent peripheral neuropathy have prompted recommendations to reserve fluoroquinolones for infections without suitable alternatives.

Metronidazole and rifampin represent important DNA-acting agents with distinct mechanisms and clinical niches. Metronidazole is reduced by anaerobic bacteria to reactive intermediates that cause DNA strand breaks, providing bactericidal activity against anaerobes and certain parasites while lacking activity against aerobic organisms. First-line indications include Clostridioides difficile infection, bacterial vaginosis, trichomoniasis, and anaerobic infections when combined with aerobic coverage. Rifampin inhibits DNA-dependent RNA polymerase, blocking transcription, and serves as a cornerstone of tuberculosis therapy while also providing synergistic activity when combined with other agents for staphylococcal prosthetic device infections. Nitrofurantoin acts through multiple mechanisms involving DNA damage and is concentrated in urine, making it specifically useful for uncomplicated urinary tract infections with minimal systemic distribution.

<image>Panel A: Fluoroquinolone mechanism showing DNA gyrase and topoisomerase IV bound to DNA, with fluoroquinolones stabilizing the enzyme-DNA complex and causing double-strand breaks, plus generational differences in spectrum. Panel B: Dual-target model explaining gram-negative versus gram-positive specificity with DNA gyrase as primary target in gram-negatives and topoisomerase IV as primary in gram-positives, with sequential mutation steps for resistance. Panel C: Fluoroquinolone toxicities on body diagram showing CNS effects including seizures and psychosis, cardiac QT prolongation, musculoskeletal tendon rupture with risk factors, metabolic glucose dysregulation, and peripheral neuropathy. Panel D: Metronidazole reduction pathway showing prodrug activation by anaerobic bacteria, rifampin binding to RNA polymerase, and nitrofurantoin urinary concentration with primary clinical indications.</image>

VII. Folate Inhibitors and Other Antibiotics

The folate synthesis pathway provides an essential target for antimicrobial therapy because bacteria must synthesize folate de novo while humans obtain folate from dietary sources. Sulfonamides inhibit dihydropteroate synthase, the enzyme that combines para-aminobenzoic acid with pteridine to form dihydropteroic acid, the precursor to dihydrofolic acid. Trimethoprim inhibits dihydrofolate reductase, the enzyme that reduces dihydrofolic acid to tetrahydrofolic acid, the active cofactor required for one-carbon transfer reactions in nucleotide synthesis. The combination of sulfamethoxazole and trimethoprim achieves sequential blockade of the same pathway, resulting in synergistic bactericidal activity that exceeds what either agent achieves alone.

Trimethoprim-sulfamethoxazole provides broad-spectrum coverage making it a versatile agent for numerous clinical scenarios. Urinary tract infections remain a primary indication, though rising resistance rates in some regions have reduced empiric utility. The combination serves as first-line prophylaxis and treatment for Pneumocystis jirovecii pneumonia in immunocompromised patients, particularly those with HIV/AIDS. Community-acquired MRSA skin and soft tissue infections respond well to oral TMP-SMX, providing an accessible outpatient alternative to intravenous vancomycin. Significant toxicities include hypersensitivity reactions ranging from rash to Stevens-Johnson syndrome, myelosuppression from folate antagonism, and hyperkalemia from trimethoprim's effect on renal potassium excretion.

Polymyxins have re-emerged as critical agents for treating multidrug-resistant gram-negative infections despite significant toxicity profiles. Colistin, a polymyxin B derivative, disrupts bacterial outer membranes through detergent-like activity, causing rapid bactericidal killing of gram-negative organisms including many carbapenem-resistant strains. The mechanism involves binding to lipopolysaccharide in the outer membrane, disrupting membrane integrity and causing cell lysis. Nephrotoxicity and neurotoxicity represent major limitations, with acute kidney injury occurring in 30-60% of patients receiving systemic therapy. These agents are typically reserved as last-resort options when no other effective antibiotics are available.

Fosfomycin represents a unique cell wall synthesis inhibitor that blocks an early step in peptidoglycan precursor formation by inhibiting MurA enzyme. The drug is administered as a single oral dose for uncomplicated urinary tract infections, achieving high urinary concentrations despite limited systemic distribution. Fosfomycin maintains activity against many extended-spectrum beta-lactamase-producing organisms and vancomycin-resistant Enterococcus urinary isolates, providing an important option for resistant infections. Low resistance rates have been maintained through limited use and the multiple mutations required for resistance development, making fosfomycin a valuable reserve agent.

<image>Panel A: Folate synthesis pathway showing PABA plus pteridine converted by dihydropteroate synthase blocked by sulfonamides to dihydropteroic acid, then to dihydrofolic acid reduced by dihydrofolate reductase blocked by trimethoprim to tetrahydrofolic acid, demonstrating sequential blockade and synergy. Panel B: TMP-SMX clinical uses including UTIs, PCP prophylaxis and treatment, CA-MRSA skin infections, with toxicities including rash, Stevens-Johnson syndrome, myelosuppression, and hyperkalemia. Panel C: Polymyxin mechanism showing molecule binding to LPS in gram-negative outer membrane causing membrane disruption and cell lysis, with nephrotoxicity and neurotoxicity indicators and last resort designation. Panel D: Fosfomycin mechanism showing MurA enzyme inhibition in early peptidoglycan synthesis with single-dose regimen, urinary concentration, and activity against ESBL and VRE organisms.</image>

VIII. Antifungal Agents

Antifungal agents target structures and pathways unique to fungal cells, with ergosterol serving as the primary distinguishing feature from mammalian cholesterol-containing membranes. Polyene antifungals, exemplified by amphotericin B, bind directly to ergosterol in the fungal membrane, creating pores that allow leakage of cellular contents and rapid fungicidal killing. Azole antifungals inhibit lanosterol 14-alpha-demethylase, a cytochrome P450 enzyme required for ergosterol synthesis, resulting in membrane instability and fungistatic or fungicidal activity depending on the organism and concentration. Echinocandins target beta-1,3-glucan synthase, blocking synthesis of an essential cell wall polysaccharide unique to fungi, while allylamines inhibit squalene epoxidase, another enzyme in the ergosterol synthesis pathway.

Amphotericin B remains the broadest-spectrum antifungal, with activity against most pathogenic fungi including yeasts, molds, and dimorphic fungi. The conventional deoxycholate formulation carries significant nephrotoxicity risk, causing dose-dependent renal tubular damage that limits cumulative dosing. Lipid formulations, including liposomal amphotericin B, provide equivalent efficacy with substantially reduced nephrotoxicity by altering drug distribution and reducing renal accumulation. Infusion reactions characterized by fever, rigors, and hypotension occur commonly and can be mitigated by premedication with acetaminophen, diphenhydramine, and hydrocortisone.

Azole antifungals vary widely in their spectrum and clinical applications despite sharing a common mechanism. Fluconazole provides excellent activity against most Candida species and Cryptococcus neoformans but lacks activity against Aspergillus and some Candida species including Candida krusei and Candida glabrata. Voriconazole extends coverage to include Aspergillus species and resistant Candida, serving as first-line therapy for invasive aspergillosis, though visual disturbances and hepatotoxicity require monitoring. Posaconazole adds activity against Zygomycetes including Mucor species, while isavuconazole provides similar broad coverage with improved tolerability. All azoles inhibit CYP3A4, causing significant drug interactions with immunosuppressants, anticoagulants, and numerous other medications.

Echinocandins have become first-line agents for invasive candidiasis due to their excellent safety profile and reliable activity against resistant Candida species. Caspofungin, micafungin, and anidulafungin share similar spectra, with activity against Candida species including azole-resistant strains and Aspergillus species, though Aspergillus infections may require combination therapy. These agents lack activity against Cryptococcus and Zygomycetes due to differences in cell wall composition in these organisms. Intravenous-only administration limits outpatient use, but the favorable toxicity profile makes echinocandins preferred for empiric therapy in critically ill patients with suspected invasive fungal infections.

<image>Panel A: Fungal cell with major antifungal targets showing cell membrane ergosterol targeted by polyenes, ergosterol synthesis pathway enzymes targeted by azoles and allylamines, and cell wall beta-glucan targeted by echinocandins. Panel B: Amphotericin B mechanism showing ergosterol binding and pore formation in fungal membrane with comparison of conventional versus lipid formulations, nephrotoxicity rates, and infusion reaction management. Panel C: Azole spectrum comparison chart showing fluconazole, voriconazole, posaconazole, and isavuconazole activity against Candida species, Cryptococcus, Aspergillus, and Mucor with CYP3A4 interaction warning. Panel D: Echinocandin mechanism showing beta-glucan synthase inhibition with spectrum coverage of Candida and Aspergillus but not Cryptococcus or Mucor, plus advantages of safety and azole-resistant activity and limitations of IV-only administration.</image>

IX. Antiviral Agents

Antiviral agents targeting herpesviruses share a common mechanism requiring viral thymidine kinase for initial phosphorylation, providing selectivity for infected cells. Acyclovir, the prototype agent, is converted by viral thymidine kinase to acyclovir monophosphate, then by cellular kinases to the active triphosphate form that inhibits viral DNA polymerase and causes chain termination. Valacyclovir, the valine ester prodrug of acyclovir, provides improved oral bioavailability reaching 55% compared to acyclovir's 15-30%, allowing less frequent dosing while achieving similar drug exposures. Ganciclovir exhibits enhanced activity against cytomegalovirus due to additional phosphorylation by CMV-encoded UL97 kinase, but causes significant myelosuppression limiting its use to serious CMV disease.

Influenza antivirals include neuraminidase inhibitors and newer agents targeting viral replication machinery. Oseltamivir inhibits the neuraminidase enzyme required for release of newly formed virions from infected cells, preventing viral spread when initiated within 48 hours of symptom onset. Zanamivir provides similar activity through inhalation delivery, useful for patients unable to take oral medications, while peramivir offers a single intravenous dose option. Baloxavir marboxil represents a novel mechanism, inhibiting the cap-dependent endonuclease required for viral mRNA synthesis, providing single-dose oral treatment that reduces viral shedding more rapidly than neuraminidase inhibitors.

Human immunodeficiency virus treatment has evolved to highly effective combination antiretroviral therapy using drugs targeting multiple steps in the viral lifecycle. Nucleoside reverse transcriptase inhibitors, including tenofovir and emtricitabine, incorporate into growing viral DNA and cause chain termination, forming the backbone of most regimens. Non-nucleoside reverse transcriptase inhibitors directly bind and allosterically inhibit the enzyme, while protease inhibitors prevent cleavage of viral polyproteins into functional components. Integrase strand transfer inhibitors, now preferred as the third agent in most regimens, block viral DNA integration into host chromosomes, with dolutegravir and bictegravir providing high genetic barriers to resistance. Entry inhibitors including the CCR5 antagonist maraviroc block viral attachment and fusion for patients with CCR5-tropic virus.

Hepatitis treatment has been transformed by direct-acting antivirals achieving cure rates exceeding 95% for hepatitis C virus infection. Sofosbuvir inhibits the NS5B RNA-dependent RNA polymerase, forming the backbone of most HCV regimens combined with NS5A inhibitors such as ledipasvir or velpatasvir. Treatment courses of 8-12 weeks achieve sustained virologic response, effectively curing infection in most patients without interferon or ribavirin. Hepatitis B treatment relies on nucleoside analogs including tenofovir and entecavir that suppress viral replication but rarely achieve cure, requiring indefinite therapy in most patients to maintain viral suppression and prevent disease progression.

<image>Panel A: Herpesvirus antiviral activation pathway showing viral thymidine kinase converting acyclovir to monophosphate, cellular kinases converting to triphosphate that inhibits viral DNA polymerase and causes chain termination, with comparison of acyclovir, valacyclovir, and ganciclovir characteristics. Panel B: Influenza drug mechanisms showing neuraminidase inhibitors oseltamivir and zanamivir blocking virion release, and baloxavir inhibiting cap-dependent endonuclease for mRNA synthesis, with 48-hour treatment timing window. Panel C: HIV lifecycle with drug class targets including entry blocked by CCR5 antagonist maraviroc, reverse transcription blocked by NRTIs and NNRTIs, integration blocked by INSTIs, and protease cleavage blocked by PIs. Panel D: HCV versus HBV treatment comparison showing HCV with NS5B inhibitor sofosbuvir plus NS5A inhibitor achieving greater than 95% cure in 8-12 weeks versus HBV nucleoside analog suppression requiring lifelong therapy.</image>

X. Antimicrobial Resistance and Stewardship

Antimicrobial resistance mechanisms have evolved across all pathogen classes, threatening the continued utility of available agents and demanding new approaches to treatment and prevention. Enzymatic inactivation, exemplified by beta-lactamases, directly degrades antibiotics before they can reach their targets, with extended-spectrum beta-lactamases and carbapenemases representing progressively more concerning resistance determinants. Target modification alters drug binding sites to prevent antimicrobial activity, as seen in altered penicillin-binding proteins conferring methicillin resistance and ribosomal modifications conferring macrolide resistance. Efflux pumps actively export antibiotics from bacterial cells, while decreased permeability through porin mutations limits drug entry, with both mechanisms often combining with other resistance determinants in multidrug-resistant organisms.

Important resistant organisms present significant clinical and public health challenges requiring coordinated responses. Methicillin-resistant Staphylococcus aureus carries the mecA gene encoding PBP2a, a modified penicillin-binding protein with low beta-lactam affinity, requiring treatment with vancomycin, daptomycin, or linezolid for serious infections. Vancomycin-resistant Enterococcus has modified peptidoglycan precursors preventing vancomycin binding, with daptomycin and linezolid serving as primary treatment options. Extended-spectrum beta-lactamase-producing Enterobacteriaceae hydrolyze most cephalosporins, traditionally requiring carbapenems, though newer beta-lactamase inhibitor combinations provide alternatives. Carbapenem-resistant Enterobacteriaceae represent the most concerning threat, often susceptible only to polymyxins, tigecycline, or newer agents like ceftazidime-avibactam.

Antimicrobial stewardship programs implement evidence-based practices to optimize antibiotic use, improve patient outcomes, and slow resistance development. Selecting the right drug requires matching antibiotic spectrum to documented or suspected pathogens, using culture data and local antibiograms to guide empiric therapy. Right dose optimization applies pharmacokinetic and pharmacodynamic principles to achieve therapeutic exposures while minimizing toxicity. Right duration initiatives have demonstrated that shorter courses often achieve equivalent outcomes with reduced resistance selection pressure and adverse events. De-escalation from broad-spectrum empiric therapy to narrower targeted agents once culture results are available reduces collateral damage to normal flora and resistance selection.

Prevention strategies complement treatment optimization in comprehensive antimicrobial resistance control programs. Infection control practices including hand hygiene, contact precautions, and environmental cleaning interrupt transmission of resistant organisms in healthcare settings. Vaccination prevents infections that might otherwise require antibiotic treatment, reducing overall antibiotic consumption and resistance pressure. Appropriate prescribing in outpatient settings addresses the large volume of unnecessary antibiotic use for viral infections, patient demand, and diagnostic uncertainty. Surveillance systems track resistance trends to inform empiric therapy guidelines and identify emerging threats requiring immediate response, creating feedback loops that continuously improve antimicrobial use practices.

<image>Panel A: Four major resistance mechanisms in bacterial cell showing enzymatic inactivation by beta-lactamases destroying antibiotics, target modification with altered PBPs and ribosomes, efflux pumps actively removing drugs, and decreased permeability from mutated porins blocking entry. Panel B: Important resistant organisms hierarchy showing MRSA with mecA and PBP2a, VRE with D-Ala-D-Lac, ESBL-producing Enterobacteriaceae, CRE with carbapenemases, and MDR Pseudomonas with treatment options and threat levels. Panel C: Stewardship principles as circular flow showing right drug with spectrum matching and culture guidance, right dose with PK/PD optimization, right duration as shortest effective, and de-escalation with IV-to-PO conversion, with improved outcomes at center. Panel D: Prevention strategies showing infection control with hand hygiene and isolation precautions, vaccination preventing infections, appropriate prescribing practices, and surveillance of resistance trends all reducing resistance emergence.</image>

Summary

• Beta-lactams inhibit cell wall synthesis through PBP binding; includes penicillins, cephalosporins (generations 1-5), carbapenems, and monobactams
• Cephalosporin generations progress from gram-positive (1st) to gram-negative coverage (3rd-4th), with 5th generation adding MRSA activity
• Vancomycin binds D-Ala-D-Ala for gram-positive coverage including MRSA; requires AUC-based dosing to optimize efficacy and minimize nephrotoxicity
• Aminoglycosides target 30S ribosome with concentration-dependent killing; nephrotoxicity and ototoxicity require monitoring
• Macrolides inhibit 50S ribosome translocation; cover atypical pathogens but cause QT prolongation
• Fluoroquinolones inhibit DNA gyrase and topoisomerase IV; black box warnings for tendon rupture, QT prolongation, neuropathy
• TMP-SMX provides synergistic folate pathway inhibition for UTIs, PCP, and CA-MRSA
• Antifungals target ergosterol (polyenes, azoles) or beta-glucan (echinocandins); azoles cause significant CYP3A4 interactions
• Antivirals include nucleoside analogs (acyclovir, ganciclovir for herpes; tenofovir for HIV/HBV), neuraminidase inhibitors (oseltamivir for influenza), and direct-acting antivirals (sofosbuvir for HCV)
• Resistance mechanisms include enzymatic inactivation, target modification, efflux, and decreased permeability; stewardship optimizes prescribing to preserve antibiotic utility

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown